305 related articles for article (PubMed ID: 19349176)
1. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Bénardeau A; Benz J; Binggeli A; Blum D; Boehringer M; Grether U; Hilpert H; Kuhn B; Märki HP; Meyer M; Püntener K; Raab S; Ruf A; Schlatter D; Mohr P
Bioorg Med Chem Lett; 2009 May; 19(9):2468-73. PubMed ID: 19349176
[TBL] [Abstract][Full Text] [Related]
2. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
4. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Lecka-Czernik B
IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Kim E; Park CS; Han T; Bae MH; Chong W; Lee CH; Shin YA; Ahn BN; Kim MK; Shin CY; Son MH; Kim JK; Moon HS; Shim HJ; Kim EJ; Kim SH; Lim JI; Lee CH
Bioorg Med Chem Lett; 2008 Sep; 18(18):4993-6. PubMed ID: 18771917
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
Kuhn B; Hilpert H; Benz J; Binggeli A; Grether U; Humm R; Märki HP; Meyer M; Mohr P
Bioorg Med Chem Lett; 2006 Aug; 16(15):4016-20. PubMed ID: 16737814
[TBL] [Abstract][Full Text] [Related]
7. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
8. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Pingali H; Jain M; Shah S; Makadia P; Zaware P; Goel A; Patel M; Giri S; Patel H; Patel P
Bioorg Med Chem; 2008 Aug; 16(15):7117-27. PubMed ID: 18625559
[TBL] [Abstract][Full Text] [Related]
11. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.
Ye XY; Li YX; Farrelly D; Flynn N; Gu L; Locke KT; Lippy J; O'Malley K; Twamley C; Zhang L; Ryono DE; Zahler R; Hariharan N; Cheng PT
Bioorg Med Chem Lett; 2008 Jun; 18(12):3545-50. PubMed ID: 18511276
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Zhang H; Ryono DE; Devasthale P; Wang W; O'Malley K; Farrelly D; Gu L; Harrity T; Cap M; Chu C; Locke K; Zhang L; Lippy J; Kunselman L; Morgan N; Flynn N; Moore L; Hosagrahara V; Zhang L; Kadiyala P; Xu C; Doweyko AM; Bell A; Chang C; Muckelbauer J; Zahler R; Hariharan N; Cheng PT
Bioorg Med Chem Lett; 2009 Mar; 19(5):1451-6. PubMed ID: 19201606
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
Lu Y; Guo Z; Guo Y; Feng J; Chu F
Bioorg Med Chem Lett; 2006 Feb; 16(4):915-9. PubMed ID: 16300944
[TBL] [Abstract][Full Text] [Related]
16. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
Bioorg Med Chem Lett; 2009 May; 19(10):2683-7. PubMed ID: 19376700
[TBL] [Abstract][Full Text] [Related]
17. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
[TBL] [Abstract][Full Text] [Related]
18. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
19. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
[TBL] [Abstract][Full Text] [Related]
20. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Raval P; Jain M; Goswami A; Basu S; Gite A; Godha A; Pingali H; Raval S; Giri S; Suthar D; Shah M; Patel P
Bioorg Med Chem Lett; 2011 May; 21(10):3103-9. PubMed ID: 21450468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
